TWI293290B - - Google Patents
Download PDFInfo
- Publication number
- TWI293290B TWI293290B TW090126305A TW90126305A TWI293290B TW I293290 B TWI293290 B TW I293290B TW 090126305 A TW090126305 A TW 090126305A TW 90126305 A TW90126305 A TW 90126305A TW I293290 B TWI293290 B TW I293290B
- Authority
- TW
- Taiwan
- Prior art keywords
- crystal
- solvent
- type crystal
- crystals
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
1293290 Α7 Β7 五、發明説明(1 ) 【發明背景】 本發明係有關爲糖尿病藥有用之拿貼利〔化合物名: N -(反式一 4 -異丙基環己烷羰基)一 D -苯基丙氨酸 〕之製造方法。更詳細爲,本發明係有關實質上不含有Η 型.結晶的拿貼利Β型結晶之製造方法。 拿貼利爲,藉由經口投與顯示有良好的降血糖作用, 爲糖尿病治療藥有用而被得知(特公平4 - 1 5 2 2 1號 公報)。 又,拿貼利具有多形結晶,其中Η型結晶因有用而被 得知。惟,爲離析Η型結晶,必須嚴密控制晶析條件,小 心進行晶析,有晶析操作困難的問題(參照特許第 2508949號公報)。 一方面,其他多形結晶之一的Β型結晶,藉由於晶析 時進行冷卻晶析,有容易製造的優點。惟,此Β型結晶於 製造階段有可能轉移成Η型結晶,事實上,以拿貼利的工 業規模進行製造時,判明所取得之Β型結晶中混入了 η型 結晶。爲醫藥品使用的拿貼利’理想爲儘可能避免多形結 晶的混入,因如果可能只以單一結晶形爲最佳,因此期待 開發出可提供只含有其Β型結晶之醫藥製劑,不混入結晶 多形的拿貼利Β型結晶之製造方法。 【發明開示】 本發明係提供無混入其他結晶形的Β型拿貼利結晶於 工業上之製造方法爲目的。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 1-----!1#! (請先閲讀背面之注意事項再填寫本頁) 、11 經濟部智慧財產局員工消費合作社印製 -4、 1293290 A7 __ B7 五、發明説明(2) 本發明者等以有效利用拿貼利B型結晶爲目的進行硏 究’藉由選擇於拿貼利的製造階段之條件,發現單一結晶 形的拿貼利B型結晶可以工業規模製造,進而完成本發明 〇 亦即,本發明係提供包含拿貼利的溶媒合物濕潤結晶 於低溫下乾燥至溶媒消失後,使結晶轉移,實質上不含有 Η型結晶的拿貼利B型結晶之製造方法。 本發明之理想係提供包含自含有拿貼利的溶液中,藉 由冷卻晶析,析出取得拿貼利水合物之溶媒合物,於溫度 5 0 °C以下,乾燥至溶媒消失,並且實質上溶媒合物不存 在後,包含加熱至6 0〜1 1 0 °C使結晶轉移至B型結晶 ,實質上不含有Η型結晶的拿貼利B型結晶之製造方法。 【爲實施發明之最佳形態】 使用於本發明之拿貼利的溶媒合物的濕潤結晶爲,甲 醇,乙醇或異丙醇等乙醇類,乙酸甲酯或乙酸乙酯等乙酸 酯類,或水的溶媒合物可被列舉出。拿貼利的溶媒合物的 濕潤結晶通常使甩乙醇混合物及水合物等。乙醇混合物的 場合,例如藉由使拿貼利的濃度成爲5重量%,加入至 6 0 %的乙醇水中,於3 0 °C左右溶解後,使此冷卻至 1 0 °C以下,即可進行調製。 其中,因水合物爲於拿貼利的乙醇溶液,理想爲乙醇 溶液中加入水,冷卻至1 〇 °C以下析出結晶,藉由分離此 而容易取得,因此較理想。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) I-----— If, (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 -5- 1293290 A7 B7 五、發明説明(3) 將所取得之溶媒合物的濕潤結晶乾燥至溶媒消失。此 時的溫度雖因附著於結晶上之溶媒種類及量而有所不同, 通常爲6 0 °C以下,理想爲5 0 °C以下。最低溫度雖無特 別指示,但從經濟的觀點看來,通常在2 0 °C以上進行。 乾燥通常於減壓下進行較理想,於工業上儘可能提高減壓 度,較能於短時間內完成乾燥。 於低溫之乾燥,實質上雖持續至溶媒消失,但並不需 至完全消失,即使殘存5重量%左右的溶媒,於結晶轉移 時也會消失,因此不會有問題。 所取得之乾燥結晶,藉由加熱至6 0〜1 1 0 °C,理 想爲7 0〜1 0 0 °C,使其轉移成B型結晶。結晶轉移通 常之理想爲進行0 · 5〜4 8小時,更理想爲1〜2 4小 .時。 B型結晶中的Η型結晶可藉由使用D S C分析。拿貼 利Β型結晶爲,以D S C測定時,Η型結晶爲不被檢測出 者較理想。 乾燥濕潤狀態的拿貼利溶媒合物結晶時,於實驗室規 模的小規模的場合,因分離結晶時的殘存溶媒量少,且又 達到乾燥器之最高減壓的速度快,於最初階段提高乾燥溫 度並無太大問題,但以工業規模,例如一次製造相當於5 k g以上的情況下,自晶析液中所分離出之結晶中所殘存 的溶媒量多,且又因乾燥時達到最高減壓度的時間相較之 下需時較長,藉由本發明之方法,可製造出不含有Η型結 晶之Β型結晶。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) I-----丨丨丨参丨— (請先閲讀背面之注意事項再填寫本頁) 、1Τ 經濟部智慧財產局員工消費合作社印製 -6 - 1293290 A7 B7 五、發明説明(4) 以下,藉由實施例,進行本發明更具體之說明,惟本 發明並不被限定於此實施例。 實施例1 將拿貼利Η型結晶2 4 . 5 k g加入至乙醇3 6 0 L 中,於室溫下攪拌使其溶解。於此中加入水2 4 0 L,確 認溶解後冷卻至5 °C,更於5 t下使其熟成1小時。分離 所析出之結晶,得到濕結晶4.3 . 0 k g。使此於盤式乾 燥器中,以4 5 °C,乾燥2 4小時(水份含量約1 w t % ),更以9 0 °C加熱1 2小時使結晶轉移,得到乾燥結晶 1 3 · 3 k g。測定此結晶的D S C,因檢測出B型結晶 特有的峰値(熔點約1 3 0 °C ),但無檢測出Η型結晶特 有的峰値(熔點約1 3 9 °C ),得到所取得之結晶只有Β 型結晶,實質上不含有Η型結晶之結論。 比較例1 將拿貼利Η型結晶3 7 . 0 k g加入至乙醇5 4 0 L 中,於室溫下攪拌使其溶解。於此中加入水3 6 0 L,確 認溶解後冷卻至5 °C,更於5 °C下使其熟成1小時。分離 所析出之結晶’得到濕結晶4 6 · 7 k g。使此於錐形乾 燥器中,以3 〇 °C,乾燥3小時(水份含量約1 〇 w t % ),更以9 0 °C加熱1 2小時使結晶轉移,得到乾燥結晶 2 5 . 9 k g。測定此結晶的D S C,除B型結晶之外, 也觀察到Η型結晶的峰値。 本紙張尺度適财關家鮮(CNS ) Α4· ( 21GX297公釐)~' ' I-----111#! (請先閱讀背面之注意事項再填寫本頁) 、1Τ 經濟部智慧財產局員工消費合作社印製 -7 - 1293290 - A7 _—_ B7 ___ 五、發明説明(5) 比較例2 將拿貼利Η型結晶3 7 , 0 k g加入至乙醇5 4 0 L 中,於室溫下攪拌使其溶解。於此中加入水3 6 0 L,確 認溶解後冷卻至5 °C,更於5 °C下使其熟成1小時。分離 所析出之結晶,得到濕結晶4 4 · 5 k g。使此於錐形乾 燥器中,以3 0 °C,乾燥3小時(水份含量約1 0 w t % ),更以9 0 °C加熱15小時使結晶轉移,得到乾燥6型 結晶2 6 · 6 k g。測定此結晶的D S C,除B型結晶之 外,也觀察到Η型結晶的峰値。 藉由使用本發明之條件,可以工業規模製造出不存在 其他結晶形的拿貼利Β型結晶,可提供拿貼利Β型結晶爲 單一拿貼利結晶含有之便宜的醫藥製劑。 ΙΊ---------- (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 率 標 家 國 國 i中 一用 適 釐 π 9 2
Claims (1)
- A8 B8 C8 D8 1293290 六、申[範爆ϋ 第901 26305號專利申請案 中文申請專利範圍修正本 (請先閲·«背面之注意事項再填寫本頁) 民國96年2月14日修正 1 · 一種拿貼利Β型結晶之製造方法,其爲包含將拿 貼利的溶媒合物濕潤結晶於2 0〜6 0 t的低溫下乾燥至 溶媒爲5 w t %以下後,藉由於6 0〜1 1 〇 t:加熱使結 晶轉移至B型結晶者。 2 ·如申請專利範圍第1項之拿貼利B型結晶之製造 方法,其中該溶媒合物濕潤結晶爲水合物。 3 ·如申請專利範圍第1項之拿貼利B型結晶之製造 方法,其中拿貼利溶媒合物濕潤結晶的低溫乾燥與結晶轉 移的兩步驟爲以工業規模進行之步驟。 4 . 一種拿貼利B型結晶之製造方法,其係包含自含 有拿貼利的溶液中,藉由冷卻晶析,析出取得拿貼利水合 物之溶媒合物,於2 0〜6 0 °C的溫度以下,乾燥至溶媒 爲5 w t %以下,於6 0〜1 1 0 °C加熱使結晶轉移至B 型結晶者。 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)-1 -
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000324375 | 2000-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI293290B true TWI293290B (zh) | 2008-02-11 |
Family
ID=18801920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090126305A TWI293290B (zh) | 2000-10-24 | 2001-10-24 |
Country Status (18)
Country | Link |
---|---|
US (2) | US20030229249A1 (zh) |
EP (1) | EP1334964B1 (zh) |
JP (1) | JP4225057B2 (zh) |
KR (1) | KR100810930B1 (zh) |
CN (1) | CN100422143C (zh) |
AT (1) | ATE370115T1 (zh) |
AU (1) | AU2001296001A1 (zh) |
BR (1) | BR0114846A (zh) |
CA (1) | CA2426745C (zh) |
CY (1) | CY1106839T1 (zh) |
DE (1) | DE60130014T2 (zh) |
DK (1) | DK1334964T3 (zh) |
ES (1) | ES2288997T3 (zh) |
MX (1) | MXPA03003575A (zh) |
PT (1) | PT1334964E (zh) |
RU (1) | RU2275354C2 (zh) |
TW (1) | TWI293290B (zh) |
WO (1) | WO2002034713A1 (zh) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0109336A (pt) * | 2000-03-17 | 2003-06-24 | Ajinomoto C0 Inc | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico |
DE60130575T2 (de) * | 2000-10-18 | 2008-04-30 | Ajinomoto Co., Inc. | Verfahren zur herstellung von acylphenylalaninen |
ES2291356T3 (es) * | 2000-10-18 | 2008-03-01 | Ajinomoto Co., Inc. | Procedimiento para producir cristales de nateglinida. |
MXPA03003686A (es) * | 2000-10-24 | 2004-01-26 | Ajinomoto Kk | Preparaciones hidrofilas de farmaco que contienen nateglinida. |
ATE406885T1 (de) * | 2000-10-24 | 2008-09-15 | Ajinomoto Kk | Nateglinid enthaltende präparate |
EP2261202A1 (en) * | 2002-04-15 | 2010-12-15 | Ajinomoto Co., Inc. | New nateglinide crystals |
US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
US7534913B2 (en) * | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
AU2003253971A1 (en) * | 2002-07-18 | 2004-02-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
ATE349418T1 (de) * | 2003-11-26 | 2007-01-15 | A M S A Anonima Materie Sint E | Verfahren zur herstellung von nateglinidin der b- form |
KR20070009726A (ko) * | 2004-05-07 | 2007-01-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 나테글리나이드의 다형태 |
US20070231393A1 (en) * | 2004-05-19 | 2007-10-04 | University Of South Carolina | System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles |
US20080096970A1 (en) * | 2004-05-20 | 2008-04-24 | Sundaram Venkataraman | Stable Nateglinide Form B Compositions |
US7425648B2 (en) | 2005-01-03 | 2008-09-16 | A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. | Process for the preparation of nateglinide, preferably in B-form |
EP1891971A4 (en) * | 2005-01-31 | 2010-02-03 | Ajinomoto Kk | MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA |
WO2007135533A1 (en) * | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
KR100837843B1 (ko) * | 2006-12-26 | 2008-06-13 | 씨제이제일제당 (주) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 |
KR20130087485A (ko) | 2010-06-14 | 2013-08-06 | 씨아이피엘에이 엘티디. | 나테글리니드의 제조 방법 |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
EP2847161A4 (en) * | 2012-05-08 | 2015-12-23 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING DIABETES |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
EP2852569B1 (en) | 2012-05-23 | 2020-10-14 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
EP2892878A4 (en) | 2012-09-08 | 2016-02-24 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CN107207403A (zh) | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
CN107108535B (zh) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐 |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
CN104402756B (zh) * | 2014-11-27 | 2016-08-31 | 天方药业有限公司 | 一种高纯度那格列奈的制备方法 |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
JP6679616B2 (ja) | 2015-01-06 | 2020-04-22 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 炎症及び疼痛の治療のための組成物及び方法 |
CN109369443A (zh) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种新的那格列奈h晶型的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
EP0526171B1 (en) | 1991-07-30 | 1997-03-05 | Ajinomoto Co., Inc. | Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them |
DE69740161D1 (de) * | 1996-11-15 | 2011-05-12 | Ajinomoto Kk | Nateglinide-Tablettenzubereitungen |
US6844006B1 (en) * | 1999-07-09 | 2005-01-18 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
WO2001047557A1 (fr) * | 1999-12-28 | 2001-07-05 | Ajinomoto Co., Inc. | Preparations orales pour diabetes |
BR0109336A (pt) * | 2000-03-17 | 2003-06-24 | Ajinomoto C0 Inc | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico |
ES2291356T3 (es) * | 2000-10-18 | 2008-03-01 | Ajinomoto Co., Inc. | Procedimiento para producir cristales de nateglinida. |
DE60130575T2 (de) * | 2000-10-18 | 2008-04-30 | Ajinomoto Co., Inc. | Verfahren zur herstellung von acylphenylalaninen |
ATE406885T1 (de) * | 2000-10-24 | 2008-09-15 | Ajinomoto Kk | Nateglinid enthaltende präparate |
US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
-
2001
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active IP Right Cessation
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja active IP Right Grant
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
-
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2426745C (en) | 2009-09-15 |
CN1483018A (zh) | 2004-03-17 |
EP1334964A4 (en) | 2005-09-28 |
DE60130014T2 (de) | 2008-05-08 |
JP4225057B2 (ja) | 2009-02-18 |
DK1334964T3 (da) | 2007-09-24 |
DE60130014D1 (de) | 2007-09-27 |
JPWO2002034713A1 (ja) | 2004-03-04 |
KR100810930B1 (ko) | 2008-03-10 |
CY1106839T1 (el) | 2012-05-23 |
EP1334964A1 (en) | 2003-08-13 |
US20070232829A1 (en) | 2007-10-04 |
RU2275354C2 (ru) | 2006-04-27 |
ATE370115T1 (de) | 2007-09-15 |
MXPA03003575A (es) | 2003-07-14 |
PT1334964E (pt) | 2007-09-20 |
AU2001296001A1 (en) | 2002-05-06 |
CN100422143C (zh) | 2008-10-01 |
US7544834B2 (en) | 2009-06-09 |
BR0114846A (pt) | 2004-02-25 |
EP1334964B1 (en) | 2007-08-15 |
ES2288997T3 (es) | 2008-02-01 |
US20030229249A1 (en) | 2003-12-11 |
CA2426745A1 (en) | 2003-04-23 |
WO2002034713A1 (fr) | 2002-05-02 |
KR20030059212A (ko) | 2003-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI293290B (zh) | ||
JP3753155B2 (ja) | 4−アセトキシ−2α−ベンゾイルオキシ−5β,20−エポキシ−1,7β,10β−トリヒドロキシ−9−オキソ−タキセ−11−エン−13α−イル(2R,3S)−3−tert−ブトキシカルボニアミノ−2−ヒドロキシ−3−フェニルプロピオネート三水和物の製造法 | |
TW531527B (en) | Novel Modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene, and processes for their preparation | |
TW200300020A (en) | α-form or β-form crystal of acetanilide derivatives | |
JP2005509025A5 (zh) | ||
WO2011054917A1 (en) | Process for the production of polymorph form i of agomelatine | |
US6506938B1 (en) | Process for the purifying of iopamidol | |
AU2001272872B2 (en) | Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide | |
AU2001272872A1 (en) | Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide | |
TW518326B (en) | A process for producing n-(4-fluorophenyl)-n-(1-methylethyl)-2-[(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-oxy]-acetamide | |
TW514635B (en) | Method and apparatus for preparing isophthalic acid from metaxylene | |
CN109553611A (zh) | 利伐沙班中间体的制备方法和用途 | |
WO2003087039A1 (fr) | Nouveau cristal de nateglinide | |
JP2702519B2 (ja) | 多形結晶形態の転換法 | |
CN103242291A (zh) | 一种多晶型高含量苯甲酸阿格列汀的批量生产工艺 | |
US20050090552A1 (en) | Polymorphic forms of nateglinide | |
JPH06192228A (ja) | 結晶性(r)−(−)−2−シクロヘプチル−n−メチルスルフオニル−[4−(2−キノリニルメトキシ)−フエニル]−アセトアミド | |
JP4080545B2 (ja) | (s)−n,n′−ビス[2−ヒドロキシ−1−(ヒドロキシメチル)エチル]−5−[(2−ヒドロキシ−1−オキソプロピル)アミノ]−2,4,6−トリヨード−1,3−ベンゼンジカルボキシアミドを直鎖状または分岐状の(c5〜c6)アルコールまたはそれらの混合物から結晶化させる方法 | |
WO2014000555A1 (zh) | 制备依非韦伦i型结晶的方法 | |
JP3208971B2 (ja) | O,o’−ジアシル酒石酸の製造方法 | |
JP2019524811A (ja) | ヒドロニドンの製造方法 | |
CN112358436B (zh) | 一种1,2-环戊二甲酰亚胺的制备方法 | |
JPS597142A (ja) | γ型グリシンの製造方法 | |
OA12354A (en) | Tartrate salts of thiazolidinedione derivative. | |
JP2009173569A (ja) | ビス{2−〔2−(4−ジベンゾ〔b,f〕〔1,4〕チアゼピン−11−イル−1−ピペラジニル)エトキシ〕エタノール}モノフマレートの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |